

Lunsumio[®]
mosunetuzumab-axgb
injection for intravenous use 1 mg | 30 mg

Lunsumio **VELO**[™]
mosunetuzumab-axgb
subcutaneous injection 5 mg | 45 mg

Questions to ask your care team

Use this guide to prepare for your next appointment

If you have follicular lymphoma (FL) that has come back or that did not respond to 2 or more previous treatments, you may have questions about your options. Use this guide when you talk to your healthcare provider about the next steps in your journey, including selecting a treatment plan and determining if LUNSUMIO[®] or LUNSUMIO VELO[™] may be right for you.



The Patient Resource Center

is here to guide you and your caregiver to the right resources

Call **(877) GENENTECH (436-3683)**

Monday-Friday, 6 AM-5 PM PST

Learn more at www.LUNSUMIO.com

What is LUNSUMIO or LUNSUMIO VELO?

LUNSUMIO (mosunetuzumab-axgb) or LUNSUMIO VELO is a prescription medicine used to treat adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who have already received two or more treatments.

It is not known if LUNSUMIO or LUNSUMIO VELO is safe and effective in children.

The conditional approval for this use is based on response rate. There are ongoing studies to establish how well the drug works.

What is the most important information I should know about LUNSUMIO or LUNSUMIO VELO?

LUNSUMIO or LUNSUMIO VELO can cause Cytokine Release Syndrome (CRS), a serious side effect that is common during treatment with LUNSUMIO or LUNSUMIO VELO, and can also be severe or life-threatening.

Please see Important Safety Information, including **Serious Side Effects**, as well as the LUNSUMIO full [Prescribing Information](#) and [Medication Guide](#) and LUNSUMIO VELO full [Prescribing Information](#) and [Medication Guide](#).

Understanding my treatment options:

What should the goals of my treatment plan be, and why?

What are my treatment options and their risks and benefits?

Is remission possible with LUNSUMIO® or LUNSUMIO VELO™?

What are the main differences between LUNSUMIO VELO subcutaneous injection and LUNSUMIO intravenous (IV) infusion?

Is a subcutaneous injection or an intravenous infusion right for me?

Would a subcutaneous injection help me spend less time in the clinic?

How many treatment visits should I anticipate? How long will I stay on treatment?

What side effects might I experience while on treatment?

Preparing for my treatment:

How long will my treatment visit be? Where will it take place?

Do I need to take premedications at home prior to treatment?

What symptoms should I monitor myself for at home?

What can I do to improve my overall treatment experience and reduce side effects?

How will you monitor my response to treatment?

How can I tell if the treatment is working?

Please see Important Safety Information, including **Serious Side Effects**, as well as the LUNSUMIO full [Prescribing Information](#) and [Medication Guide](#) and LUNSUMIO VELO full [Prescribing Information](#) and [Medication Guide](#).

Lunsumio[®]
mosunetuzumab-axgb
injection for intravenous use 1 mg | 30 mg

Lunsumio **VELO**[™]
mosunetuzumab-axgb
subcutaneous injection 5 mg | 45 mg

After treatment with LUNSUMIO® or LUNSUMIO VELO™:

What type of follow-up will I need after treatment, and when?

What can I expect after treatment completion?

Getting the right support:

Who can I call on my care team to help me with the following topics?

- Paying for treatment or access to financial support programs
- Staying healthy (nutrition and movement)
- Accessing mental health support
- Getting a ride to and from my treatment center
- Finding a community/local support group
- Other (eg, about FL, about treatment, side effects)

Notes:

Important Safety Information (cont'd)

What is the most important information I should know about LUNSUMIO or LUNSUMIO VELO? (cont'd)

Get medical help right away if you develop any signs or symptoms of CRS at any time, including:

- fever of 100.4°F (38°C) or higher
- chills
- low blood pressure
- fast or irregular heartbeat
- tiredness or weakness
- difficulty breathing
- headache
- confusion
- feeling anxious
- dizziness or light-headedness
- nausea
- vomiting

Please see Important Safety Information, including **Serious Side Effects**, as well as the LUNSUMIO full [Prescribing Information](#) and [Medication Guide](#) and LUNSUMIO VELO full [Prescribing Information](#) and [Medication Guide](#).

Lunsumio[®]
mosunetuzumab-axgb
injection for intravenous use 1 mg | 30 mg

Lunsumio **VELO**[™]
mosunetuzumab-axgb
subcutaneous injection 5 mg | 45 mg

Important Safety Information (cont'd)

What is the most important information I should know about LUNSUMIO or LUNSUMIO VELO? (cont'd)

Due to the risk of CRS, you will receive LUNSUMIO or LUNSUMIO VELO on a “step-up dosing schedule.”

- The step-up dosing schedule is when you receive smaller “step-up” doses before receiving higher doses of LUNSUMIO or LUNSUMIO VELO during your first cycle of treatment
- If your dose of LUNSUMIO or LUNSUMIO VELO is delayed for any reason, you may need to repeat the “step-up dosing schedule”
- You may receive medicines to help reduce your risk of CRS before your dose

Your healthcare provider will check you for CRS during treatment with LUNSUMIO or LUNSUMIO VELO and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment with LUNSUMIO or LUNSUMIO VELO, if you have severe side effects.

What are the possible side effects of LUNSUMIO or LUNSUMIO VELO?

LUNSUMIO or LUNSUMIO VELO can cause serious side effects, including:

- **Neurologic problems.** LUNSUMIO or LUNSUMIO VELO can cause serious and life-threatening neurologic problems. Your healthcare provider will check you for neurologic problems during treatment with LUNSUMIO or LUNSUMIO VELO. Your healthcare provider may also refer you to a healthcare provider who specializes in neurologic problems. Tell your healthcare provider right away if you develop any signs or symptoms of neurologic problems during or after treatment with LUNSUMIO or LUNSUMIO VELO, including:

- headache
- numbness and tingling of the arms, legs, hands, or feet
- dizziness
- confusion and disorientation
- difficulty paying attention or understanding things
- forgetting things or forgetting who or where you are
- trouble speaking, reading, or writing
- sleepiness or trouble sleeping
- tremors
- loss of consciousness
- seizures
- muscle problems or muscle weakness
- loss of balance or trouble walking
- tiredness

- **Serious infections.** LUNSUMIO or LUNSUMIO VELO can cause serious infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment. Tell your healthcare provider right away if you develop any signs or symptoms of infection during treatment with LUNSUMIO or LUNSUMIO VELO, including:

- fever of 100.4°F (38°C) or higher
- cough
- chest pain
- tiredness
- shortness of breath
- painful rash
- sore throat
- pain during urination
- feeling weak or generally unwell

- **Hemophagocytic lymphohistiocytosis (HLH).** LUNSUMIO or LUNSUMIO VELO can cause overactivity of the immune system, a condition called hemophagocytic lymphohistiocytosis. HLH can be life-threatening and has led to death in people treated with LUNSUMIO or LUNSUMIO VELO. Your healthcare provider will check you for HLH especially if your CRS lasts longer than expected. Signs and symptoms of HLH include:

- fever
- enlarged spleen
- easy bruising
- low blood cell counts
- liver problems

- **Low blood cell counts.** Low blood cell counts are common during treatment with LUNSUMIO or LUNSUMIO VELO and can also be serious or severe. Your healthcare provider will check your blood cell counts during treatment with LUNSUMIO or LUNSUMIO VELO. LUNSUMIO or LUNSUMIO VELO can cause the following low blood cell counts:

- **low white blood cell counts (lymphopenia [for LUNSUMIO VELO only] and neutropenia).** Low white blood cells can increase your risk for infection
- **low red blood cell counts (anemia).** Low red blood cells can cause tiredness and shortness of breath
- **low platelet counts (thrombocytopenia).** Low platelet counts can cause bruising or bleeding problems

Please see Important Safety Information, including **Serious Side Effects**, as well as the LUNSUMIO® full [Prescribing Information](#) and [Medication Guide](#) and LUNSUMIO VELO™ full [Prescribing Information](#) and [Medication Guide](#).

Lunsumio[®]
mosunetuzumab-axgb
injection for intravenous use 1 mg | 30 mg

Lunsumio **VELO**[™]
mosunetuzumab-axgb
subcutaneous injection 5 mg | 45 mg

Important Safety Information (cont'd)

What are the possible side effects of LUNSUMIO or LUNSUMIO VELO? (cont'd)

LUNSUMIO or LUNSUMIO VELO can cause serious side effects, including: (cont'd)

- **Growth in your tumor or worsening of tumor-related problems (tumor flare).** LUNSUMIO or LUNSUMIO VELO can cause serious or severe worsening of your tumor. Tell your healthcare provider if you develop any of these signs or symptoms of tumor flare during your treatment with LUNSUMIO or LUNSUMIO VELO:

- chest pain
- cough
- trouble breathing
- tender or swollen lymph nodes
- pain or swelling at the site of the tumor

Your healthcare provider may temporarily stop or permanently stop treatment with LUNSUMIO or LUNSUMIO VELO if you develop severe side effects.

The most common side effects of LUNSUMIO include: CRS, tiredness, rash, headache, fever, muscle pain, cough, itching, and numbness, tingling, or pain in the hands or feet (nerve damage).

The most common side effects of LUNSUMIO VELO include: injection site reactions, tiredness, rash, CRS, COVID-19, muscle and joint pain, and diarrhea.

The most common severe abnormal blood test results with LUNSUMIO include: decreased phosphate, increased glucose, and increased uric acid levels.

The most common severe abnormal blood test results with LUNSUMIO VELO include: decreased white blood cell counts and increased uric acid levels.

Before receiving LUNSUMIO or LUNSUMIO VELO, tell your healthcare provider about all of your medical conditions, including if you:

- have ever had an infusion reaction after receiving LUNSUMIO
- have an infection or have had an infection in the past which lasted a long time or keeps coming back
- have or have had Epstein-Barr Virus
- are pregnant or plan to become pregnant. LUNSUMIO or LUNSUMIO VELO may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with LUNSUMIO or LUNSUMIO VELO

Females who are able to become pregnant:

- your healthcare provider should do a pregnancy test before you start treatment with LUNSUMIO or LUNSUMIO VELO
- use an effective method of birth control (contraception) during your treatment and for 3 months after the last dose of LUNSUMIO or LUNSUMIO VELO
- are breastfeeding or plan to breastfeed. It is not known if LUNSUMIO or LUNSUMIO VELO passes into your breast milk. Do not breastfeed during treatment and for 3 months after the last dose of LUNSUMIO or LUNSUMIO VELO

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What should I avoid while receiving LUNSUMIO or LUNSUMIO VELO?

Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of CRS or neurologic problems.

These are not all of the possible side effects of LUNSUMIO or LUNSUMIO VELO. Talk to your healthcare provider for more information about the benefits and risks of LUNSUMIO or LUNSUMIO VELO.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see Important Safety Information, including **Serious Side Effects**, as well as the LUNSUMIO® full [Prescribing Information](#) and [Medication Guide](#) and LUNSUMIO VELO™ full [Prescribing Information](#) and [Medication Guide](#).

Lunsumio
mosunetuzumab-axgb
injection for intravenous use 1 mg | 30 mg

Lunsumio VELO
mosunetuzumab-axgb
subcutaneous injection 5 mg | 45 mg

Genentech
A Member of the Roche Group